Geode Capital Management LLC Has $1.93 Million Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

Geode Capital Management LLC decreased its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,750 shares of the company’s stock after selling 3,088 shares during the quarter. Geode Capital Management LLC’s holdings in Fresenius Medical Care were worth $1,933,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP lifted its holdings in Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after acquiring an additional 581 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after purchasing an additional 1,675 shares during the period. ORG Wealth Partners LLC acquired a new stake in shares of Fresenius Medical Care during the third quarter worth about $112,000. Venturi Wealth Management LLC lifted its holdings in shares of Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after purchasing an additional 4,800 shares in the last quarter. Finally, Kimelman & Baird LLC acquired a new position in shares of Fresenius Medical Care in the 2nd quarter valued at approximately $186,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on FMS shares. Truist Financial raised their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. StockNews.com started coverage on shares of Fresenius Medical Care in a research note on Friday, January 3rd. They issued a “strong-buy” rating for the company. Finally, Berenberg Bank initiated coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company.

Fresenius Medical Care Trading Down 1.2 %

NYSE:FMS opened at $22.40 on Thursday. The company has a market cap of $13.14 billion, a P/E ratio of 18.51, a price-to-earnings-growth ratio of 0.95 and a beta of 0.92. Fresenius Medical Care AG has a twelve month low of $17.93 and a twelve month high of $24.31. The business has a 50 day moving average price of $22.39 and a two-hundred day moving average price of $20.73. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.